Literature DB >> 6984012

Human MHC class II molecules as differentiation markers.

V van Heyningen, K Guy, R Newman, C M Steel.   

Abstract

DA6.231 and DA6.164 are mouse monoclonal antibodies that immunoprecipitate HLA-DR-like p34,29 glycoprotein dimers from surface- and metabolically-labeled cells. On lymphoblastoid cell lines the distribution of the 231 epitope is completely nonpolymorphic, while the 164 epitope is present on all cells except on those that are DR7 homozygous. Binding-inhibition studies show that the 231 and 164 epitopes are spatially close to each other when present on the same molecule. The mutual inhibition pattern and the absence of the 164 epitope from the 231+ cells of a few leukemia patients suggest, however, that 231 and 164 epitopes are not invariably present together. Most DR-positive cells possess 231+ and 164+ and 231+ 164- class II molecules in approximately a 2:1 ratio. This has been confirmed by immune depletion studies. Thus DA6.231 appears to define a supralocus epitope. The 164 epitope may be a marker for a subset of class II molecules exhibiting differential expression on various cell types immortalized by malignant transformation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6984012     DOI: 10.1007/BF00372104

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  22 in total

1.  Polymorphism of human B-cell alloantigens: evidence for three loci within the HLA system.

Authors:  M L Markert; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

2.  Serologic and immunochemical characterization of the specificity of four monoclonal antibodies to distinct antigenic determinants expressed on subpopulations of human Ia-like antigens.

Authors:  V Quaranta; M A Pellegrino; S Ferrone
Journal:  J Immunol       Date:  1981-02       Impact factor: 5.422

3.  Biochemical and immunologic heterogeneity of Ia glycoproteins isolated from a chronic lymphocytic leukemia.

Authors:  M Letarte; J Falk
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

4.  Two populations of Ia-like molecules on a human B cell line.

Authors:  L A Lampson; R Levy
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

5.  Isolation of I-A subregion-like molecules from subhuman primates and man.

Authors:  S M Goyert; J Silver
Journal:  Nature       Date:  1981-11-19       Impact factor: 49.962

6.  Ia antigens contain two distinct forms of beta chain.

Authors:  N Koch; G J Hämmerling
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

7.  Demonstration of two distinct light chains in HLA-DR-associated antigens by two-dimensional gel electrophoresis.

Authors:  T A de Kretser; M J Crumpton; J G Bodmer; W F Bodmer
Journal:  Eur J Immunol       Date:  1982-03       Impact factor: 5.532

8.  Analysis of the biosynthesis of HLA-DR glycoproteins in human malignant melanoma cell lines.

Authors:  K O Lloyd; J Ng; W G Dippold
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

9.  Evidence for a new segregant series of B cell antigens that are encoded in the HLA-D region and that stimulate secondary allogenic proliferative and cytotoxic responses.

Authors:  S Shaw; A H Johnson; G M Shearer
Journal:  J Exp Med       Date:  1980-09-01       Impact factor: 14.307

10.  Two-gene control of the expression of a murine Ia antigen.

Authors:  P P Jones; D B Murphy; H O McDevitt
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

View more
  26 in total

1.  DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms.

Authors:  Cornelia H Rinderknecht; Sujin Roh; Achal Pashine; Michael P Belmares; Namrata S Patil; Ning Lu; Phi Truong; Tieying Hou; Claudia Macaubas; Taejin Yoon; Nan Wang; Robert Busch; Elizabeth D Mellins
Journal:  Immunology       Date:  2010-04-12       Impact factor: 7.397

2.  Candida arthritis: cellular immune responses of synovial fluid and peripheral blood lymphocytes to Candida albicans.

Authors:  E Hermann; W J Mayet; O Klein; A W Lohse; C Trautwein; I Michiels; T Poralla; K H Meyer zum Büschenfelde
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

3.  Interpretation of the specificities of monoclonal antibodies recognising human MHC class II antigens.

Authors:  K Guy; C M Steel
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

4.  Differential MHC class II expression on human peripheral blood monocytes and dendritic cells.

Authors:  C F Brooks; M Moore
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

5.  Presentation of an immunodominant T-cell epitope of hepatitis B surface antigen by the HLA-DPw4 molecule.

Authors:  E Celis; R W Karr
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

6.  Presentation of a soluble bacterial antigen and cell-surface alloantigens by large granular lymphocytes (LGL) in comparison with monocytes.

Authors:  C F Brooks; M Moore
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

7.  The expression of class II MHC gene products by fallopian tube epithelium in pregnancy and throughout the menstrual cycle.

Authors:  J N Bulmer; U Earl
Journal:  Immunology       Date:  1987-06       Impact factor: 7.397

8.  Quantitative immunological differences between newly diagnosed Graves' disease patients and relapsed patients.

Authors:  U Di Mario; F P Cavatorta; R Perfetti; G Pugliese; P Pozzilli; J Sutherland; M Vitillo; D Andreani
Journal:  J Endocrinol Invest       Date:  1988-02       Impact factor: 4.256

9.  Differential expression of HLA class II antigens on human fetal and adult lymphocytes and macrophages.

Authors:  J A Edwards; D B Jones; P R Evans; J L Smith
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

10.  Heterogeneity of non-lymphoid cells expressing HLA-D region antigens in human fetal gut.

Authors:  J Spencer; T T MacDonald; P G Isaacson
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.